We also found high and low expression groups of MAPK4 have a significant difference in the overall survival with a p-value < 0.05 in LUAD, LUSC, PAAD, THCA, UCEC, and UVM patients. This evidence concerns the gene MAPK4 and pancreatic adenocarcinoma.